Schedule 13G ownership disclosure
Sionna Therapeutics Inc
Common Stock, $0.001 par value per share · CUSIP: 829401108
Event date: 2025-02-10
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- VIKING GLOBAL INVESTORS LP
Shares: 2,952,754 · Class: 6.7%
- Viking Global Opportunities Parent GP LLC
Shares: 2,952,754 · Class: 6.7%
- Viking Global Opportunities GP LLC
Shares: 1,894,346 · Class: 4.3%
- Viking Global Opportunities Portfolio GP LLC
Shares: 1,894,346 · Class: 4.3%
- Viking Global Opportunities Illiquid Investments Sub-Master LP
Shares: 1,894,346 · Class: 4.3%
- Viking Global Opportunities Drawdown GP LLC
Shares: 1,058,408 · Class: 2.4%
- Viking Global Opportunities Drawdown Portfolio GP LLC
Shares: 1,058,408 · Class: 2.4%
- Viking Global Opportunities Drawdown (Aggregator) LP
Shares: 1,058,408 · Class: 2.4%
- HALVORSEN OLE ANDREAS
Shares: 2,952,754 · Class: 6.7%
- Ott David C.
Shares: 2,952,754 · Class: 6.7%
- Shabet Rose Sharon
Shares: 2,952,754 · Class: 6.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000905148-25-000694
- Form type
- SCHEDULE 13G
- Filer
- Sionna Therapeutics, Inc.
- CIK
- CIK 2036042
- Filed
- Feb 14, 2025
- Reporting period
- Feb 10, 2025
- Description
- Schedule 13G beneficial ownership